Does Priority Health Cover Eliquis?

What Eliquis Is and Why Coverage Matters

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that inhibits Factor Xa in the coagulation cascade. The FDA approved it in 2012 for reducing stroke risk in patients with nonvalvular atrial fibrillation, and it has since gained indications for treating deep vein thrombosis (DVT), pulmonary embolism (PE), and preventing recurrent venous thromboembolism 1.

A Widely Prescribed Anticoagulant

Apixaban became the most prescribed oral anticoagulant in the United States by 2020, with more than 30 million prescriptions dispensed annually according to IQVIA data. That volume reflects both physician confidence in the drug and patient preference for a medication that does not require routine INR monitoring.

Why the Cost Question Is Urgent

Without insurance, a 30-day supply of Eliquis costs roughly $600 to $700 at most retail pharmacies. For the estimated 6.1 million Americans living with atrial fibrillation 2, out-of-pocket burden directly affects adherence. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% versus warfarin (HR 0.79, 95% CI 0.66 to 0.95) and lowered major bleeding by 31% 3. Gaps in coverage that force patients off therapy can erase those benefits within weeks.

Priority Health's Role in Michigan

Priority Health is one of the largest health insurers in Michigan, covering more than 1 million members across commercial, Medicaid, and Medicare Advantage product lines. Understanding how this specific carrier handles Eliquis determines whether a significant portion of Michigan residents can afford the anticoagulant their cardiologist prescribed.

How Priority Health Formularies Classify Eliquis

Priority Health maintains separate formularies for its commercial HMO, commercial PPO, Health Savings Account (HSA) compatible, Medicaid, and Medicare Advantage plans. Eliquis placement shifts across these products.

Commercial Plan Tiers

On most Priority Health commercial formularies, Eliquis sits on Tier 3, which the plan labels "preferred brand." Tier 3 drugs carry a copay that typically falls between $35 and $90 per 30-day fill, depending on the member's specific benefit design. Some employer-sponsored Priority Health plans use a coinsurance model instead of flat copays. In those cases, members may owe 20% to 40% of the negotiated drug cost after meeting their deductible.

Medicare Advantage Placement

Priority Health's Medicare Advantage plans often place Eliquis on Tier 4 (non-preferred brand) or Tier 5 (specialty). Medicare Part D coverage phases add complexity. During the initial coverage phase, a Tier 4 copay might run $90 to $120 for a 30-day supply. Once a member enters the coverage gap (the so-called "donut hole"), the Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective as of 2025, limits total Part D spending 4.

Medicaid (Priority Health Choice)

Priority Health Choice, the carrier's Medicaid managed-care product, covers Eliquis with minimal or zero copay for eligible beneficiaries. Michigan Medicaid generally requires prescribers to document an FDA-approved indication and, for atrial fibrillation patients, a CHA₂DS₂-VASc score of 2 or greater in men and 3 or greater in women, consistent with the 2019 AHA/ACC/HRS Focused Update 5.

Prior Authorization and Step Therapy Requirements

Not every Priority Health member can fill an Eliquis prescription without extra paperwork. The plan applies utilization management tools selectively.

When Prior Authorization Applies

Priority Health Medicare Advantage plans commonly require prior authorization for Eliquis. The prescriber must submit documentation confirming:

• A confirmed diagnosis (atrial fibrillation, DVT, PE, or post-surgical prophylaxis)
• Relevant lab work (renal function via serum creatinine or eGFR, hepatic function)
• A CHA₂DS₂-VASc score for atrial fibrillation patients
• Reason warfarin is not appropriate, if applicable

Turnaround time for standard prior authorization is typically 72 hours. Urgent requests may be processed within 24 hours.

Step Therapy Protocols

Some Priority Health commercial plans enforce step therapy, requiring documentation that the patient tried warfarin (or that warfarin is contraindicated) before approving Eliquis. The 2023 ACC Expert Consensus Decision Pathway on Anticoagulation in Atrial Fibrillation states that DOACs are "recommended in preference to warfarin" for most patients with nonvalvular AF 6. Physicians can cite this guideline when requesting a step therapy override.

How to Handle a Denial

If Priority Health denies Eliquis coverage, the member or prescriber has 60 days to file an internal appeal. The appeal should include:

1. A letter of medical necessity from the prescribing physician
2. Relevant clinical trial data supporting apixaban over alternatives
3. Documentation of any prior adverse reactions to warfarin or other anticoagulants
4. The patient's bleeding risk score (HAS-BLED) if applicable

If the internal appeal fails, Michigan law allows an external review through the state's Department of Insurance and Financial Services (DIFS).

What You Will Actually Pay Out of Pocket

The sticker price of Eliquis is not what most Priority Health members pay. Several mechanisms reduce real-world costs.

Copay Ranges by Plan Type

A practical breakdown of expected monthly costs:

| Plan Type | Typical Tier | Estimated Monthly Cost | |---|---|---| | Commercial HMO | Tier 3 | $35, $65 copay | | Commercial PPO | Tier 3 | $45, $90 copay | | HSA-compatible | Tier 3 | Full cost until deductible met, then $35, $65 | | Medicare Advantage | Tier 4 to 5 | $90, $120 (initial coverage phase) | | Medicaid (Priority Health Choice) | Preferred | $0, $3 |

The BMS/Pfizer Savings Card

Bristol-Myers Squibb and Pfizer offer a co-pay savings card that reduces out-of-pocket costs to as little as $10 per month for commercially insured patients. This card does not apply to government-funded plans (Medicare, Medicaid, Tricare, VA). Priority Health commercial members should verify eligibility through the manufacturer's program, as savings cards typically cap annual benefits at $6,400 7.

Pharmacy Channel and Mail Order

Priority Health incentivizes 90-day fills through its preferred mail-order pharmacy. Members who use mail order often receive a discount equivalent to two copays for a three-month supply rather than three. For a Tier 3 drug with a $50 copay, that means paying $100 for 90 days instead of $150.

Clinical Evidence Supporting Eliquis Coverage

Insurers base formulary decisions partly on clinical evidence. The data supporting apixaban is extensive.

The ARISTOTLE Trial

The landmark ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to dose-adjusted warfarin in patients with atrial fibrillation and at least one stroke risk factor. Apixaban reduced stroke or systemic embolism by 21% (1.27% vs. 1.60% per year, P=0.01 for superiority). All-cause mortality fell by 11% (3.52% vs. 3.94% per year, P=0.047). Major bleeding occurred at a rate of 2.13% per year with apixaban versus 3.09% with warfarin (P<0.001) 3.

The AMPLIFY Trial for VTE

In the AMPLIFY trial (N=5,395), apixaban demonstrated noninferiority to standard therapy (enoxaparin followed by warfarin) for recurrent VTE (2.3% vs. 2.7%, P<0.001 for noninferiority). Major bleeding was 69% lower with apixaban (0.6% vs. 1.8%, relative risk 0.31) 8. These results explain why the American Society of Hematology 2020 guidelines recommend DOACs over vitamin K antagonists for most VTE patients 9.

Real-World Adherence Data

A 2022 retrospective cohort study published in the Journal of the American Heart Association (N=64,661) found that DOAC users had 28% higher medication adherence at 12 months compared to warfarin users (PDC ≥0.80: 61.2% vs. 47.8%) 10. As the 2023 AHA/ACC guideline notes, "the clinical benefit of anticoagulation is directly dependent on sustained adherence," making cost-related non-adherence a clinical concern, not merely a financial one 6.

Alternatives If Coverage Is Denied or Unaffordable

If Eliquis remains too expensive on a Priority Health plan, several alternatives exist.

Other DOACs on Formulary

Priority Health formularies typically include rivaroxaban (Xarelto), which may sit on a different tier. Some plans place edoxaban (Savaysa) on a lower tier for VTE indications. Dabigatran (Pradaxa) is another option, though it requires twice-daily dosing and has a different side-effect profile. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily was superior to warfarin for stroke prevention but carried a higher rate of gastrointestinal bleeding 11.

Warfarin as a Lower-Cost Option

Generic warfarin costs $4 to $15 per month. The trade-off is significant: warfarin requires regular INR monitoring (typically every 2 to 4 weeks), has extensive food and drug interactions, and carries a narrower therapeutic window. For patients without transportation barriers, limited polypharmacy, and stable dietary habits, warfarin remains clinically acceptable per ACC/AHA guidelines, though DOACs are preferred 6.

Patient Assistance Programs

The Bristol-Myers Squibb Patient Assistance Foundation provides Eliquis at no cost to uninsured or underinsured patients who meet income criteria (generally at or below 300% of the federal poverty level). Medicare Part D beneficiaries who fall into coverage gaps may also qualify for the Extra Help/Low-Income Subsidy program administered by the Social Security Administration 12.

How to Verify Your Specific Coverage

Formulary details change annually, and employer-sponsored benefit designs vary within the same carrier.

Check the Online Formulary Tool

Priority Health publishes searchable formulary lists on its member portal. Log in, manage to "Pharmacy" or "Drug Formulary," and search for "apixaban" or "Eliquis." The result will show the tier, any quantity limits, prior authorization flags, and step therapy requirements specific to your plan.

Call the Number on Your ID Card

The pharmacy benefits phone number on the back of your Priority Health card connects you to a benefits specialist who can confirm your exact copay, deductible status, and whether prior authorization has already been submitted.

Ask Your Pharmacist to Run a Test Claim

Any retail pharmacy can submit a test claim to Priority Health's pharmacy benefit manager. This returns the exact amount you would owe at the counter, accounting for your deductible progress and any applied discounts. A test claim takes less than two minutes.

Switching Plans During Open Enrollment

If your current Priority Health plan makes Eliquis prohibitively expensive, open enrollment (typically November through mid-January for Medicare Advantage and employer plans) is the time to compare options.

What to Compare

Look beyond monthly premiums. A plan with a $20 lower premium but a $60 higher Tier 3 copay costs more over 12 months if you take a daily brand-name medication. Priority Health offers a plan comparison tool that estimates total annual drug costs based on your current medication list.

The Medicare Plan Finder

Medicare-eligible members can use the CMS Medicare Plan Finder at medicare.gov to compare all available Medicare Advantage and Part D plans in their zip code. Enter "apixaban" into the drug list, and the tool ranks plans by estimated total annual cost, including premiums, deductibles, and copays 4.

When Generic Apixaban May Arrive

Patent exclusivity for Eliquis has been the subject of extensive litigation. Bristol-Myers Squibb and Pfizer hold multiple patents, some extending into 2026 and beyond. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA.

Expected Timeline

The earliest possible generic entry was projected for late 2026, contingent on patent settlement outcomes and FDA approval timelines. When generics do reach the market, history suggests prices could drop 80% to 90% within the first two years, as occurred with generic clopidogrel (Plavix) and generic rosuvastatin (Crestor) 13.

Impact on Priority Health Coverage

Once a generic apixaban becomes available, Priority Health will likely move it to Tier 1 or Tier 2 (generic preferred), dropping copays to $5 to $20 per month. The brand-name Eliquis would then shift to a higher tier or require prior authorization demonstrating medical necessity for the brand over the generic.

Patients currently stable on Eliquis should discuss the transition with their prescriber when generics become available. Bioequivalence standards enforced by the FDA require generic apixaban to deliver the same plasma concentration curve as the brand product within an 80% to 125% confidence interval 13.